• Combination therapy with doxazosin and finasteride significantly improves IPSS, Qmax, and PVR compared to doxazosin monotherapy in BPH patients.
• Prostate volume reduction was markedly greater with combination therapy (18.2% vs. 5.4%), indicating a synergistic effect on disease progression.
• Adverse event rates were comparable between groups, suggesting that combination therapy is safe and well-tolerated.
• The study supports the use of combination therapy as a first-line treatment for moderate-to-severe BPH, potentially delaying the need for surgical intervention.